DOCSLIB.ORG

INDIA the Government Must Revitalise Public Sector Units to Meet COVID-19 Vaccine Requirements

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
INDIA the Government Must Revitalise Public Sector Units to Meet COVID-19 Vaccine Requirements 16-30 APRIL, 2021 DownToEarthSCIENCEFORTNIGHTLY AND ENVIRONMENTON POLITICS OF FORTNIGHTLY DEVELOPMENT, ENVIRONMENT AND HEALTH Subscriber copy, not for resale `60.00 AFRICA Inequitable global distribution of vaccines will only prolong the pandemic for every country AT RISK AT INDIA The government must revitalise public sector units to meet COVID-19 vaccine requirements 01Cover.indd 1 12/04/21 9:41 AM Advertisement 02JSES- Magazine Advt- Feb 2021- PDF.indd 2 09/04/21 12:32 PM SUNITA NARAIN \EDIT Zero-zero, net zero E HAVE seen furious activity on climate change in the first weeks of April in Delhi. No, I am not talking about action to fight climate change. I am talking about words and more words—much has been W written about the position that India must take or not take when it comes to declaring a net-zero goal. Much has been discussed in closed-door meetings on the same. John Kerry, the US climate envoy, was in town in the lead up to President Joe Biden’s climate leaders summit on April 22-23. He wanted to cajole and push us to act—say something big when the leaders meet. The good news is that climate change is back on the agenda. The bad news is that we are discussing the wrong things; we are in danger of once again losing the opportunity to drive home the need for ambition and equity in climate change action. Just consider the narrative in Delhi. It was not about the need to take stock of what has been done or not done to meet the Paris commitments—the voluntary targets countries have taken to reduce greenhouse gas emissions in this decade; it was not about how minuscule, completely off track and inequitable the Paris targets are. It was not about the emission pathways countries are choosing to make drastic reductions as needed to avoid the climate change catastrophe. It was not about anything that matters. Instead, the entire discourse was distracted by the completely meaningless discussion on net-zero—it is widely accepted that Joe Biden will declare his country’s net-zero target for 2050 at the summit. The question was if, should and could India follow its net-zero date? Why do I say this is meaningless? Firstly, let’s be clear that there is no substance in the net-zero target that countries have declared. It is but an aspirational idea—something that they will work towards. Practically all the countries that have made the grandstanding declaration have no plans on how they will get to net-zero by 2050, or in the case of China, by 2060. So, it means nothing. It’s about the idea of getting there and the hope that some so-called disruptive technologies will get scaled up and be ready The fact that Joe for delivery when the date comes. Biden is not a Secondly, net-zero as an idea itself is flawed. It means that countries will emit more; climate denier is but they will mop up these emissions to say "net-net". How will they soak up the good news. But it emissions? Two methods: one, plant trees that will sequester carbon dioxide that we will is not enough continue to emit and two, take the carbon dioxide and pump it back into the ground— carbon capture and storage technologies. But there are still many unanswered questions about this approach; there are huge challenges in estimating the "tree-soak" and there are issues to sort with the set of technologies, fancifully called negative emission. So, it’s a scam—at least today—to talk about these as the real options going forward. You can argue that these so-called disruptive technologies will come and so we should not be rejecting this idea today. I would say yes, but our dependence on these still experimental technologies to save us will distract attention from what can and must be done today. That needs to be our conversation. Not net-zero. Thirdly, net-zero is intrinsically inequitable. It was the Intergovernmental Panel on Climate Change (IPCC) that had said global net human-caused emissions of carbon dioxide would need to fall by 45 per cent from the 2010 levels by 2030, reaching net-zero by 2050. Given the fact that there is a huge and completely disproportionate difference in the emissions of the old-developed world and now newly developed China and the rest of the world, it would be logical to say that if the world needs to be net-zero by 2050, then these countries needed to have already turned net-zero or do so by 2030. No later. Then it would provide space for countries like India—way below in the historical emissions and current emissions—to declare a net-zero goal by 2050. In today’s scenario, what could or should India do? Declare a net-zero goal by 2070? Twenty years after the US and Europe; 10 years after China. What does it even mean? As things stand today and when Joe Biden grandstands his country into the net-zero world of 2050—do not clap. Do not cheer. It is not enough. Not by a stretch. Only ask if his country will meet the Paris commitments—so ridiculously meagre—by 2025. The US has to be 26-28 per cent below its peak levels in 2005 by 2025. In fact, US greenhouse gas emissions in 2019 were higher than that at the end of 2016. We also need real ambition by 2030, not talk of 2050. The fact that Joe Biden is not a climate denier is good news. But it's not enough. Let’s not end up losing another decade squabbling over yet another chimera. Climate change is real. It is time we stood up to it. DTE @sunitanar DOWNTOEARTH.ORG.IN 16-30 APRIL 2021 DOWN TO EARTH 3 03Editors.indd 3 09/04/21 4:00 PM Down To Earth Founded in 1992 to arm you with knowledge critical to shaping a better world FOUNDER EDITOR Anil Agarwal Contents EDITOR Sunita Narain MANAGING EDITOR Richard Mahapatra ASSOCIATE EDITORS Vibha Varshney, S S Jeevan, Snigdha Das, Arnab Pratim Dutta (Multimedia) CREATIVE DIRECTOR Ajit Bajaj SUPPLEMENT EDITOR Sorit Gupto 30 REPORTING TEAM Ishan Kukreti, Akshit Sangomla, Africa is the other Banjot Kaur, Shagun Kapil continent after ASSISTANT EDITORS Aditya Misra, Rajit Sengupta Europe which is SUB EDITOR Dakshiani Palicha under a tight grip of WEB EDITORS Joyjeet Das, Rajat Ghai, Anshika Ravi, the COVID-19's Preetha Banerjee second wave. If the DESIGN TEAM Chaitanya Chandan, Sanjit Kumar, Shri Krishan, Vijayendra Pratap Singh, Ritika Bohra world remains PHOTOGRAPHER Vikas Choudhary uninvolved, it will only PHOTO LIBRARY Anil Kumar prolong the course of the pandemic for PRODUCTION Rakesh Shrivastava, Gundhar Das every country TECH SUPPORT Rajendra Rawat, Jaidev Sharma MULTIMEDIA Sunny Gautam, Adithyan P C INFORMATION AND RESEARCH SUPPORT Kiran Pandey, Susan Chacko,Madhumita Paul, Sheeja Nair, Lalit Maurya, Dayanidhi Mishra CONSULTING EDITOR Anumita Roychowdhury 20 India must utilise Vol 29, No 23; Total No of Pages: 60 its idle public Editorial, subscriptions and advertisements: Society for Environmental Communications, sector assets to 41, Tughlakabad Institutional Area, overcome the New Delhi 110 062, COVID-19 vaccine Phone: 91-11- 40616000, 29955124, COVER STORY COVER supply crunch 29956110, 29956394, 29956399 Fax: 91-11-29955879. Email: [email protected] 2021 Society for Environmental Communications. All rights reserved throughout the world. Reproduction in any manner is prohibited. Printed and published by Richard Mahapatra on behalf of Society for Environmental Communications. Printed at International Print-o-Pac Limited, B-204, 205, Okhla Industrial Area, Phase I, New Delhi-110020, India, and published at 41, Tughlakabad Institutional Area, New Delhi 110 062. 07 Digest 54 Book excerpt To subscribe, sms 'dte Subscribe' to 56070 Uttarakhand village uses Oonga explores the or visit www.downtoearth.org.in/subscribe technology to revive a spring human impact of FOR ADVERTISEMENTS Jyoti Ghosh environmental conflict [email protected] 12 Soil FOR SUBSCRIPTIONS The world’s 175-year-long 56 Opinion K C R Raja, [email protected] agricultural study has great Water assets built under insights about farming practices MGNREGA must suit the ground typologies 18 Warm start Despite prevalence of cold 58 Civil Lines La Niña conditions, spring and Mass poverty has returned to 16-30 APRIL, 2021 summer arrive early this year India after 45 years DownToEarthSCIENCEFORTNIGHTLY AND ENVIRONMENTON POLITICS OF FORTNIGHTLY DEVELOPMENT, ENVIRONMENT AND HEALTH Subscriber copy, not for resale `60.00 AFRICA Inequitable global distribution of vaccines will only prolong the pandemic for every country 52 Patently absurd Will rights waiver make COVID-19 vaccines cheaper to produce? Probably not AT RISK AT INDIA The government must revitalise public sector units to meet COVID-19 vaccine requirements Cover design: Ajit Bajaj Cover photo: istock, Reuters 01Cover.indd 1 09/04/21 5:41 PM Down To Earth does not endorse the content of advertisements printed in the magazine. All disputes are subject to the exclusive jurisdiction of competent courts and forums in Delhi/New Delhi only. 04Contents+Credits.indd 4 12/04/21 10:12 AM Engage Nuclear is the answer This is in reference to the column “Why nuclear is still unclear” (16-31 March, 2021). The major obstacle faced by renewable energy is its low capacity factor (the ratio of actual electrical energy output of a system over a given period of time to the hypothetical maximum possible output). Since nuclear energy has the highest capacity factor of any other energy source, it clearly is the answer.
Load more

Recommended publications
  • 6Th ACT Accelerator Facilitation Council Meeting Livestreamed Virtual Meeting, 12 May 2021, 12:30 – 15:00 (CEST)
    11 May 2021 6th ACT Accelerator Facilitation Council meeting Livestreamed virtual meeting, 12 May 2021, 12:30 – 15:00 (CEST) Co-hosts: Dr Tedros Adhanom Ghebreyesus, Director General, WHO & Ms Stella Kyriakides, Commissioner for Health and Food Safety, European Commission Co-Chairs: Dr Zweli Mkhize, Minister of Health, South Africa & Mr Dag-Inge Ulstein, Minister of International Development, Norway Primary Objectives • Identify barriers and strategies for increasing uptake and use of COVID-19 tools at country level • Guide COVAX Task Force on strategies to expand COVID-19 vaccine production Draft Provisional Agenda Opening (10 min) 12h30 – Welcome • Co-Chairs & Co-Hosts opening remarks (10 12h40 min) Scale up of vaccine supply to COVAX (1hr 5 min), Chair: South Africa 12h40 – Objective: Guide COVAX Task Force on • Facilitator: Dr Ayoade Olatunbosun-Alakija 13h45 strategies to expand COVID-19 Vaccine • Presentation from Task Force (5 min) production • Interactive Panel (20 min) o Dr Amadou Sall, Director, Institut Pasteur, Senegal o Dr Patrick Soon Shiong, Chairman of the Chan Soon-Shiong Family Foundation, CEO & Chairman ImmunityBio & NantHealth o Dr Ngozi Okonjo-Iweala, Director General, WTO • Council Discussion (33 min) • Task Force comments in response to discussion (5 min) • Chair’s closing remarks (2 min) Health Systems Connector: Facilitating uptake & delivery of COVID-19 tools (60 min), Chair: Norway 13h45 – Objective: Identify barriers and strategies for • Facilitator: Emma Ross 14h45 increasing uptake and use of COVID-19 tools at • Interactive panel (20 min) country level o Dr Faisal Sultan, Special Assistant to Prime Minister on Health, Ministry of National Health Services Regulations & Coordination, Pakistan o Dr W.
    [Show full text]
  • Caste-Based Oppression and the Class Struggle TU Senan CWI-India
    Caste-based Oppression and the Class Struggle TU Senan CWI -India 24 December 2014 Leave a comment In 2013, the British government agreed to include caste- based discrimination as an amendment to the Equality Act (2010). An alliance of Tory MPs and caste-based ‘community leaders’, however, successfully stalled its implementation to after the general election. What is behind this opposition? What role does caste play, both in South Asia and Britain? Why is it an important issue for socialists today? The caste system in South Asia is one of the cruellest forms of oppression that exists today. Cold-blooded murder, sexual violence, untouchability, bonded slavery and other feudal forms of horrific discrimination are used against people from the most oppressed caste. People challenging this oppression face brutal violence, including being driven from traditional lands or the burning down of whole villages. More than half-a-billion people in India are subjected to discrimination based on their caste, which is determined by hereditary membership and marriage within the caste. Higher castes dominate certain professions, businesses, etc. Beneath this hierarchical system are more than 200 million (Dalits and others) who face the most severe forms of discrimination. Traditional castes cut across class and class loyalties, although the leaders of the higher castes are a significant component of the ruling class. Caste oppression is also present in other parts of the world where South Asians live, travelling with the migrations of populations over time. From Malaysia to Europe, caste divisions have been maintained. At least half-a- million people of South Asian descent face caste-based discrimination in Britain.
    [Show full text]
  • News Covering in the Online Press Media During the ANC Elective Conference of December 2017 Tigere Paidamoyo Muringa 212556107
    News covering in the online press media during the ANC elective conference of December 2017 Tigere Paidamoyo Muringa 212556107 A thesis submitted in fulfilment of the academic requirements for the degree of Doctor of Philosophy (PhD) at Centre for Communication, Media and Society in the School of Applied Human Sciences, College of Humanities, University of KwaZulu-Natal, Durban. Supervisor: Professor Donal McCracken 2019 As the candidate's supervisor, I agree with the submission of this thesis. …………………………………………… Professor Donal McCracken i Declaration - plagiarism I, ……………………………………….………………………., declare that 1. The research reported in this thesis, except where otherwise indicated, is my original research. 2. This thesis has not been submitted for any degree or examination at any other university. 3. This thesis does not contain other persons' data, pictures, graphs or other information unless specifically acknowledged as being sourced from other persons. 4. This thesis does not contain other persons' writing unless specifically acknowledged as being sourced from other researchers. Where other written sources have been quoted, then: a. Their words have been re-written, but the general information attributed to them has been referenced b. Where their exact words have been used, then their writing has been placed in italics and inside quotation marks and referenced. 5. This thesis does not contain text, graphics or tables copied and pasted from the Internet, unless specifically acknowledged, and the source being detailed in the thesis and the References sections. Signed ……………………………………………………………………………… ii Acknowledgements I am greatly indebted to the discipline of CCMS at Howard College, UKZN, led by Professor Ruth Teer-Tomaselli. It was the discipline’s commitment to academic research and academic excellence that attracted me to pursue this degree at CCMS (a choice that I don’t regret).
    [Show full text]
  • Cuba: One Year Into the Pandemic
    BULLETIN OF PAHO/WHO IN CUBA Vol. 25 No.1 JANUARY-MARCH 2021 CUBA: ONE YEAR INTO THE PANDEMIC 04 43 46 50 OUR NEWS: NOTEWORTHY: OVER A STORY A CUP OF TO TELL: Interview Benefits with Cuba's of a Cúrcumal onga COFFEE Dr. Ricardo Minister pdroject uring WITH… Pereda González: of Public Health, thep andemic Coordinator of Dr. José Angel Concepción the COVID-19 Clinical Portal Miranda Campa Experts Commission Huergo Pathways to Health is a bulletin prepared by the office of the Pan American Health Organization/World Health Organization EDITORIAL (PAHO/WHO) in Cuba. Its main aim is to share the most important aspects of the On March 11, 2020, the Director-General of the World Health Representation's technical cooperation with Organization (WHO) declared the novel coronavirus a pandemic, the country's Ministry of Public Health which at the time already affected 114 nations. Coincidentally, (MINSAP) and other institutions. that same day, the Pedro Kourí Tropical Medicine Institute (IPK) in Havana confirmed the first COVID-19 cases in Cuba. At the one-year anniversary of the pandemic in Cuba, this issue is dedicated to One year into the pandemic, more than 115 million cases and close to 2.6 million deaths have been reported from the disease systematically review key aspects of the worldwide. About half of both these cases and deaths have been national response over the last months. In registered in the Americas, with results differing according to how particular, it includes an interview with the well the response has been organized, how robust the healthcare Minister of Public Health, Dr.
    [Show full text]
  • A Step Towards Revising the Model for Vaccine Tuberculosis Immunity
    COMMENTARY CONTEST Revising the model for vaccine development: a step towards tuberculosis immunity Amy Dagenais1 1University of Ottawa, Ottawa, Ontario, Canada Date Published: August 26, 2021 DOI: https://doi.org/10.18192/UOJM.V11iS1.5929 Keywords: Tuberculosis, COVID-19, vaccines hanks to accelerated vaccine development, the first with the largest infectious disease burden in the world, COVID-19 vaccine was approved for use by Health tolling 10 million new infections and 1.2 million deaths Canada only nine months after the disease was in 2019 alone.² Indeed, tuberculosis is one of the top 10 Tdeclared a pandemic by the World Health Organization.¹ causes of death worldwide—but the situation remains This unprecedented feat was made possible by three underdiscussed as most cases are recorded in developing critical factors: a stressed sense of urgency, substantial areas, such as South-East Asia (44%) and Africa (25%), or funding, and parallel pre-clinical and clinical trials. Such in underserved populations such as the Inuit in Canada.2,3 a concerted effort not only led to the development of Approximately one-quarter of the world population is multiple effective vaccines, but also bred innovation as infected by the etiological agent of tuberculosis: the mRNA technology bloomed despite its limited use in the bacterium Mycobacterium tuberculosis (Mtb), known as past. This success story paves the way for the accelerated the most successful human pathogen.² development of vaccines for other diseases, such as tuberculosis—the deadliest infectious disease of modern The intracellular pathogen has co-evolved with humans times before COVID-19 emerged. to evade host immune defenses, rendering TB treatment particularly difficult.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Ending Covid Means Ending Aids, and Ending Both Means E
    Ending Covid means ending Aids, and ending both means e... MAVERICK CITIZEN: EDITORIAL Ending Covid means ending Aids, and ending both means ending inequality By Mark Heywood • 14 June 2021 Faceboo Twitter Print Email AddThis 17 Ending Covid means ending Aids and ending both means ending inequality. (Photo: forbes.… When it comes to communicable diseases, the lesson we should take from Covid-19 is that one person is all it takes to start a devastating pandemic. Is that fact enough of a wake-up for governments to seriously tackle the social and economic determinants of health and disease? https://www.dailymaverick.co.za/article/2021-06-14-ending-covid-means-ending-aids-and-ending-both-means-ending-inequality/[2021/06/15 1:25:12 PM] Ending Covid means ending Aids, and ending both means e... Last week, at the opening of the tenth South African Aids Conference, X Professor Salim Abdool Karim made a plenary presentation titled “HIV and Covid-19 in South Africa”. It revealed how interdependent the HIV/Aids and Covid-19 pandemics are becoming. Professor Salim Abdool Karim. (Photo: Dean Demos) In an overview, “SARS-CoV-2 infection in people living with HIV”, Karim referred to the case of a patient whose immune system was almost entirely suppressed because of HIV and who, as a result, experienced an acute Covid-19 infection that persisted over six months. Eventually, when she was put on to a new and effective regimen of antiretroviral medicines (ARVs) her immune system rebounded and she also recovered quickly from Covid-19. This was the good news.
    [Show full text]
  • Covid-19: South Africa Pauses Use of Oxford Vaccine After
    NEWS BMJ: first published as 10.1136/bmj.n372 on 8 February 2021. Downloaded from The BMJ Cite this as: BMJ 2021;372:n372 Covid-19: South Africa pauses use of Oxford vaccine after study casts http://dx.doi.org/10.1136/bmj.n372 doubt on efficacy against variant Published: 08 February 2021 Elisabeth Mahase Rollout of the Oxford-AstraZeneca covid-19 vaccine is going to be hard to estimate. Without seeing results in South Africa has been paused after a study in 2000 in detail it isn’t possible to be sure how firm these healthy and young volunteers reported that it did not conclusions are. protect against mild and moderate disease caused by “However, if the press reports are correct it does seem the new variant (501Y.V2) that emerged there. of concern that protection against disease was not The study, which has not been published and was shown. The findings of the Novavax vaccine trial of seen by the Financial Times,1 looked at the efficacy 60% efficacy in the prevention of disease of any of the vaccine against the 501Y.V2 variant—which severity in HIV negative volunteers in South Africa accounts for around 90% of cases in South Africa—in might also suggest that vaccines will need to be HIV negative people. While reports suggested that updated in line with emerging mutations of the the vaccine was ineffective at preventing mild to virus.” moderate disease in that population, no data have 1 Mancini DP, Kuchler H, Pilling D, Cookson C, Cotterill J. Oxford/AstraZeneca been made available to the public.
    [Show full text]
  • Update 50 (15Th of December 2020)
    Update 50 (15th of December 2020) Information about Infection disease COVID-19 (novel coronavirus) Force Health Protection Branch FHPB (former DHSC) NATO MILMED COE in Munich 15th of December 2020 email: [email protected] In December 2019, a novel coronavirus emerged in Wuhan City, China. Since then the virus spread to 65 countries including Europe and America. Since then the virus showed evidence for human-to-human transmission as well as evidence of asymptomatic transmission. At 30th January 2020 WHO declared a Public Health Emergency of International Concern. The disease was formally named COVID-19 on 11th of February. The virus itself has been named SARS-CoV-2. On 11th of March 2020 WHO characterized the disease as a pandemic. HIGHLIGHTS/NEWS GLOBALLY ↗ • GBR/WHO: A new variant of the virus could be responsible for the renewed high number of cases in the UK, among other things, which 72 879 777 confirmed cases could be "in connection with the faster spread in the south of England". 47 710 950 recovered So far, 1000 cases have been identified. 1 622 200 deaths The WHO emphasized that the new variant would now be examined. EU/EEA and the UK ↘ However, there is no evidence that the strain behaves differently than 21 936 276 existing virus types. "We saw many variants, this virus evolves and confirmed cases changes over time." 10 689 950 recovered • Sputnik V: The developers of the Russian coronavirus vaccine Sputnik 479 566 deaths V explain that it creates 91.4 percent protection against the lung disease USA ↗ Covid-19.
    [Show full text]
  • Revision Rápida
    REVISION RÁPIDA EVALUACIÓN DE LAS CARACTERÍSTICAS DE ALMACENAMIENTO, TRANSPORTE Y DISTRIBUCIÓN DE LAS VACUNAS COVID-19 EN ESTUDIO, Y LAS CARACTERÍSTICAS CLÍNICAS DE LA POBLACIÓN CANDIDATA A VACUNACIÓN Noviembre de 2020 El Instituto de Evaluación Tecnológica en Salud – IETS, es una corporación sin ánimo de lucro, de participación mixta y de carácter privado, con patrimonio propio, creado según lo estipulado en la Ley 1438 de 2011. Su misión es contribuir al desarrollo de mejores políticas públicas y prácticas asistenciales en salud, mediante la producción de información basada en evidencia, a través de la evaluación de tecnologías en salud y guías de práctica clínica, con rigor técnico, independencia y participación. Sus miembros son el Ministerio de Salud y Protección Social – MinSalud, el Departamento Administrativo de Ciencia, Tecnología e Innovación – Colciencias, el Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA, el Instituto Nacional de Salud – INS, la Asociación Colombiana de Facultades de Medicina – ASCOFAME y la Asociación Colombiana de Sociedades Científicas – ACSC. Autores Lucas López Quiceno. Médico y cirujano, Especialista en Epidemiología, Magister en Epidemiología, Magíster en economía de la salud (c). Instituto de Evaluación Tecnológica en Salud - IETS. Jhyld Carolaind Camacho Barbosa, Nutricionista y Dietista, Magister en Epidemiología. Instituto de Evaluación Tecnológica en Salud - IETS. Kelly Estrada-Orozco. Médica, Magister en Epidemiología Clínica, Magister en Neurociencia. Doctorado en Salud Pública (actual). Doctorado en Epidemiología Clínica (actual). Instituto de Evaluación Tecnológica en Salud - IETS. Revisores Cortes-Muñoz, Ani Julieth. Bacterióloga y laboratorista clínica. MSc. Epidemiología. Instituto de Evaluación Tecnológica en salud - IETS. Ospina-Lizarazo, Nathalie. Nutricionista Dietista. MSc. Epidemiología Clínica. Instituto de Evaluación Tecnológica en salud - IETS.
    [Show full text]
  • Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
    Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
    [Show full text]
  • Link 20-Apr-2021 JAMA Immunogenicity of the Ad26.COV2
    07/052021 Date Journal Title Study type Country Authors Link Trial identifier Intervention Main question To evaluate the immunogenicity of the Ad26.COV2.S vaccine Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in Immunogenicity of the Ad26.COV2.S Vaccine for Stephenson KE et https://pubmed.ncbi.nl (by Janssen 20‐Apr‐2021 JAMA RCT USA NCT04436276 humans, including the kinetics, COVID‐19 al m.nih.gov/33704352/ Pharmaceutical magnitude, and phenotype of SARS‐ Companies) CoV‐2 spike‐specific humoral and cellular immune responses Combination of To compare the rate and time of Effect of a combination of nitazoxanide, https://www.ncbi.nlm.ni nitazoxanide, viral clearance in subjects receiving J of Medical ribavirin, and ivermectin plus zinc supplement h.gov/pmc/articles/PMC ribavirin, and the combination of nitazoxanide, 11‐Mar‐2021 CT Egypt Elalfy H et al NCT04392427 Virology (MANS.NRIZ study) on the clearance of mild 8014583/pdf/JMV‐9999‐ ivermectin plus Zinc ribavirin, and ivermectin plus zinc COVID‐19 0.pdf vs supportive versus those receiving supportive treatment treatment. XAV‐19 0.5 mg/kg at Pharmacokinetics and safety of XAV‐19, a day 1 and day 5 To assess the pharmacokinetics and https://www.medrxiv.or swine glyco‐humanized polyclonal anti‐ SARS‐ (group 1), 2 mg/kg at safety of XAV‐19, a swine glyco‐ g/content/10.1101/2021 20‐Apr‐2021 MedRxiv CoV‐2 antibody, for COVID‐19‐related RCT France Gaborit B et al NCT04453384 day 1 and day 5 humanized polyclonal antibody .04.15.21255549v1.full.p (group 2), 2 mg/kg at against SARS‐CoV‐2, in COVID‐19‐ moderate pneumonia: a randomized, double‐ df blind, placebo‐controlled, phase IIa study day 1 (group 3) or related moderate pneumonia placebo https://www.nejm.org/ To assest the Safety and Efficacy of Safety and Efficacy of Single‐Dose Ad26.COV2.S Vaccine RCT III 21‐Apr‐21 NEJM International Sadoff J et al.
    [Show full text]